Create a baseline by calculating your average weight during the final week on semaglutide
Both drugs help improve insulin sensitivity while decreasing insulin resistance
Development and Expanding Indications of GLP-1 Receptor Agonists In 2005, the United States (US) Food and Drug Administration approved the first GLP-1 receptor agonist, exenatide, for the treatment of type 2 diabetes (T2D)
For broader tissue research, anti-aging biomarker research, or research questions requiring systemic distribution, injectable GHK-Cu dosage is more appropriate
No liver enzyme improvement after 8 weeks in users with elevated baseline confirm product quality (COA), consider route upgrade (oral to injectable/IV), and evaluate whether the elevation has a non-oxidative etiology
Keeping it in the shade or inside an insulated pouch makes a real difference